Annual EBITDA
-$110.66 M
-$944.00 K-0.86%
December 31, 2023
Summary
- As of February 25, 2025, FULC annual EBITDA is -$110.66 million, with the most recent change of -$944.00 thousand (-0.86%) on December 31, 2023.
- During the last 3 years, FULC annual EBITDA has fallen by -$41.43 million (-59.85%).
- FULC annual EBITDA is now -396.74% below its all-time high of -$22.28 million, reached on December 31, 2017.
Performance
FULC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$22.69 M
-$75.56 M-142.93%
September 30, 2024
Summary
- As of February 25, 2025, FULC quarterly EBITDA is -$22.69 million, with the most recent change of -$75.56 million (-142.93%) on September 30, 2024.
- Over the past year, FULC quarterly EBITDA has increased by +$4.79 million (+17.43%).
- FULC quarterly EBITDA is now -142.93% below its all-time high of $52.87 million, reached on June 30, 2024.
Performance
FULC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$26.66 M
+$4.21 M+13.65%
September 30, 2024
Summary
- As of February 25, 2025, FULC TTM EBITDA is -$26.66 million, with the most recent change of +$4.21 million (+13.65%) on September 30, 2024.
- Over the past year, FULC TTM EBITDA has increased by +$81.83 million (+75.42%).
- FULC TTM EBITDA is now -273.67% below its all-time high of -$7.14 million, reached on March 31, 2018.
Performance
FULC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
FULC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.9% | +17.4% | +75.4% |
| 3 y3 years | -59.9% | +17.4% | +75.4% |
| 5 y5 years | -244.2% | +17.4% | +75.4% |
FULC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -40.9% | at low | -142.9% | +32.4% | at high | +76.1% |
| 5 y | 5-year | -59.9% | at low | -142.9% | +32.4% | at high | +76.1% |
| alltime | all time | -396.7% | at low | -142.9% | +38.2% | -273.7% | +76.1% |
Fulcrum Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$22.69 M(-142.9%) | -$26.66 M(-13.6%) |
| Jun 2024 | - | $52.87 M(-280.1%) | -$30.88 M(-72.0%) |
| Mar 2024 | - | -$29.36 M(+6.8%) | -$110.47 M(+1.8%) |
| Dec 2023 | -$110.66 M(+0.9%) | -$27.48 M(+2.1%) | -$108.49 M(+0.1%) |
| Sep 2023 | - | -$26.91 M(+0.7%) | -$108.43 M(+3.5%) |
| Jun 2023 | - | -$26.73 M(-2.4%) | -$104.80 M(-6.1%) |
| Mar 2023 | - | -$27.37 M(-0.2%) | -$111.63 M(+1.7%) |
| Dec 2022 | -$109.72 M(+39.7%) | -$27.42 M(+17.8%) | -$109.72 M(+4.3%) |
| Sep 2022 | - | -$23.28 M(-30.6%) | -$105.24 M(+3.1%) |
| Jun 2022 | - | -$33.56 M(+31.8%) | -$102.11 M(+16.6%) |
| Mar 2022 | - | -$25.46 M(+11.0%) | -$87.56 M(+11.5%) |
| Dec 2021 | -$78.54 M | -$22.94 M(+13.8%) | -$78.54 M(+8.1%) |
| Sep 2021 | - | -$20.15 M(+6.0%) | -$72.66 M(+2.3%) |
| Jun 2021 | - | -$19.01 M(+15.6%) | -$71.05 M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$16.44 M(-3.6%) | -$67.42 M(-2.6%) |
| Dec 2020 | -$69.23 M(-15.7%) | -$17.05 M(-8.1%) | -$69.23 M(+1.6%) |
| Sep 2020 | - | -$18.55 M(+20.7%) | -$68.15 M(+3.1%) |
| Jun 2020 | - | -$15.37 M(-15.8%) | -$66.09 M(+3.8%) |
| Mar 2020 | - | -$18.26 M(+14.3%) | -$63.70 M(-22.5%) |
| Dec 2019 | -$82.16 M(+155.5%) | -$15.97 M(-3.1%) | -$82.16 M(+9.6%) |
| Sep 2019 | - | -$16.49 M(+27.0%) | -$74.94 M(+11.7%) |
| Jun 2019 | - | -$12.98 M(-64.7%) | -$67.07 M(+8.6%) |
| Mar 2019 | - | -$36.72 M(+320.1%) | -$61.74 M(+92.0%) |
| Dec 2018 | -$32.15 M(+44.3%) | -$8.74 M(+1.3%) | -$32.15 M(+37.3%) |
| Sep 2018 | - | -$8.63 M(+12.9%) | -$23.41 M(+58.4%) |
| Jun 2018 | - | -$7.65 M(+7.1%) | -$14.78 M(+107.1%) |
| Mar 2018 | - | -$7.14 M | -$7.14 M |
| Dec 2017 | -$22.28 M | - | - |
FAQ
- What is Fulcrum Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics annual EBITDA year-on-year change?
- What is Fulcrum Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics quarterly EBITDA year-on-year change?
- What is Fulcrum Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics TTM EBITDA year-on-year change?
What is Fulcrum Therapeutics annual EBITDA?
The current annual EBITDA of FULC is -$110.66 M
What is the all time high annual EBITDA for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high annual EBITDA is -$22.28 M
What is Fulcrum Therapeutics annual EBITDA year-on-year change?
Over the past year, FULC annual EBITDA has changed by -$944.00 K (-0.86%)
What is Fulcrum Therapeutics quarterly EBITDA?
The current quarterly EBITDA of FULC is -$22.69 M
What is the all time high quarterly EBITDA for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high quarterly EBITDA is $52.87 M
What is Fulcrum Therapeutics quarterly EBITDA year-on-year change?
Over the past year, FULC quarterly EBITDA has changed by +$4.79 M (+17.43%)
What is Fulcrum Therapeutics TTM EBITDA?
The current TTM EBITDA of FULC is -$26.66 M
What is the all time high TTM EBITDA for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high TTM EBITDA is -$7.14 M
What is Fulcrum Therapeutics TTM EBITDA year-on-year change?
Over the past year, FULC TTM EBITDA has changed by +$81.83 M (+75.42%)